Aude Charbonnier - Concepedia

Author

Aude Charbonnier

Also Known As

A Charbonnier, A. Charbonnier, Aude Charbonnier, Aurelien Proux, B. Mohty, Bilal Mohty, C. Saillard, Charbonnier Aude, Charbonnier, Aude, Claude Lemarie

156

Publications

6.9K

Citations

H-Index

Concepts

All Affiliations

Institut Paoli-Calmettes Inserm Hôpital Saint-Louis Institut Bergonié Centre Hospitalier Régional et Universitaire de Nancy

About

Aude Charbonnier is an author at Institut Paoli-Calmettes specializing in medicine, hematology, and oncology.

Top Concepts

#	Concept	H-Index	Publications	Citations
1	Medicine	14	17	3K
2	Health Sciences	6	6	2.3K
3	Cell Biology	4	4	72
4	Blood Transplantation	2	2	57
5	Public Health	1	1	14

Aude Charbonnier

Publications

6.3K

Citations

H-Index

Page 1

	Year	Citations
Discontinuation of imatinib in patients with chronic myeloid leukaemia who have maintained complete molecular remission for at least 2 years: the prospective, multicentre Stop Imatinib (STIM) trial François‐Xavier Mahon, Delphine Réa, Joëlle Guilhot, The Lancet Oncology Hematological MalignancyOncologyChronic Myeloid LeukaemiaHematologyMyeloid Neoplasia	2010	1.5K
Discontinuation of tyrosine kinase inhibitor therapy in chronic myeloid leukaemia (EURO-SKI): a prespecified interim analysis of a prospective, multicentre, non-randomised, trial Johan Richter, Joëlle Guilhot, Franz Gruber, The Lancet Oncology Hematological MalignancyMedicineChronic Myeloid LeukaemiaMixed-phenotype Acute LeukemiaHematology	2018	587
Intermittent Target Inhibition With Dasatinib 100 mg Once Daily Preserves Efficacy and Improves Tolerability in Imatinib-Resistant and -Intolerant Chronic-Phase Chronic Myeloid Leukemia Neil P. Shah, Hagop M. Kantarjian, Dong‐Wook Kim, Journal of Clinical Oncology	2008	487
Long-Term Follow-Up of the French Stop Imatinib (STIM1) Study in Patients With Chronic Myeloid Leukemia Gabriel Étienne, Joëlle Guilhot, Delphine Réa, Journal of Clinical Oncology Hematological MalignancyStop ImatinibChronic Myeloid LeukemiaPurpose ImatinibMedicine	2016	484
Loss of Major Molecular Response As a Trigger for Restarting Tyrosine Kinase Inhibitor Therapy in Patients With Chronic-Phase Chronic Myelogenous Leukemia Who Have Stopped Imatinib After Durable Undetectable Disease Philippe Rousselot, Aude Charbonnier, Pascale Cony‐Makhoul, Journal of Clinical Oncology	2013	405
Discontinuation of dasatinib or nilotinib in chronic myeloid leukemia: interim analysis of the STOP 2G-TKI study Delphine Réa, Franck E. Nicolini, Michel Tulliez, Blood	2016	314
Cardiovascular Toxicity Related to Cancer Treatment: A Pragmatic Approach to the American and European Cardio‐Oncology Guidelines Joachim Alexandre, Jennifer Cautela, Stéphane Éderhy, Journal of the American Heart Association	2020	283
A phase 1 trial of the anti-inhibitory KIR mAb IPH2101 for AML in complete remission Norbert Vey, Jean Bourhis, Nicolas Boissel, Blood	2012	268
Comorbidity is an independent predictor of complete remission in elderly patients receiving induction chemotherapy for acute myeloid leukemia Anne Etienne, Benjamin Esterni, Aude Charbonnier, Cancer	2007	169
Natural killer-cell counts are associated with molecular relapse-free survival after imatinib discontinuation in chronic myeloid leukemia: the IMMUNOSTIM study Delphine Réa, Guylaine Henry, Zena Khaznadar, Haematologica	2017	147

Page 1